Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
kenaiteinib
- Development stage
- Phase 1
- Lead developer
- Jiangsu Maidu Pharmaceutical Research and Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Kenaiteinib (MD-001) is an orally bioavailable small molecule tyrosine kinase inhibitor (TKI) targeting the epidermal growth factor receptor (EGFR). Developed by Jiangsu Maidu Pharmaceutical Research and Development, it is specifically designed to inhibit EGFR mutations associated with resistance and poor prognosis in non-small cell lung cancer (NSCLC), including the T790M gatekeeper mutation and exon 20 insertion mutations. These mutations often render tumors resistant to first- and second-generation EGFR TKIs. Kenaiteinib is currently being evaluated in Phase 1 clinical trials in China for patients with advanced NSCLC who have progressed on prior therapies.
- Other names
- 克耐替尼
02
Targets
Beyond the preview
Go deeper on kenaiteinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on kenaiteinib.